Vigil Neuroscience (NASDAQ:VIGL) Price Target Lowered to $13.00 at Wedbush

Vigil Neuroscience (NASDAQ:VIGL) had its price target decreased by research analysts at Wedbush from $24.00 to $13.00 in a research report issued to clients and investors on Friday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Wedbush also issued estimates for Vigil Neuroscience’s FY2029 earnings at $1.40 EPS.

Other equities research analysts have also issued reports about the stock. HC Wainwright lowered their price target on shares of Vigil Neuroscience from $17.00 to $14.00 and set a “buy” rating for the company in a report on Friday. JMP Securities reiterated a “market outperform” rating and set a $22.00 price target on shares of Vigil Neuroscience in a report on Tuesday, November 26th. William Blair began coverage on shares of Vigil Neuroscience in a report on Wednesday, December 4th. They set an “outperform” rating for the company. Finally, Guggenheim restated a “buy” rating on shares of Vigil Neuroscience in a report on Friday, January 24th. Five investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $16.25.

Vigil Neuroscience Stock Performance

Shares of Vigil Neuroscience stock opened at $2.02 on Friday. The company has a fifty day moving average of $2.34 and a 200-day moving average of $2.79. Vigil Neuroscience has a 52-week low of $1.49 and a 52-week high of $6.06. The stock has a market capitalization of $82.58 million, a price-to-earnings ratio of -0.98 and a beta of 1.82.

Vigil Neuroscience (NASDAQ:VIGL) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.08). On average, equities research analysts forecast that Vigil Neuroscience will post -2.07 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the stock. Cubist Systematic Strategies LLC raised its holdings in Vigil Neuroscience by 53.0% in the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company’s stock worth $41,000 after purchasing an additional 8,358 shares in the last quarter. Jane Street Group LLC bought a new position in shares of Vigil Neuroscience in the 4th quarter worth about $83,000. Barclays PLC increased its stake in shares of Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company’s stock worth $109,000 after acquiring an additional 19,436 shares in the last quarter. Northern Trust Corp increased its stake in shares of Vigil Neuroscience by 29.0% in the 4th quarter. Northern Trust Corp now owns 64,737 shares of the company’s stock worth $110,000 after acquiring an additional 14,572 shares in the last quarter. Finally, Two Sigma Advisers LP increased its stake in shares of Vigil Neuroscience by 243.8% in the 4th quarter. Two Sigma Advisers LP now owns 69,100 shares of the company’s stock worth $117,000 after acquiring an additional 49,000 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.